Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine versus SSRI for subjective sleep improvement in major depressive disorder
ISRCTN55250367Phase 3Completed
- Sponsor
- Servier
- Start
- May 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of agomelatine in major depressive disorder (MDD) (2 arms), sponsored by Servier. Primary endpoint: Improvement of subjective sleep. Started May 2007; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN55250367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN55250367.